Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milademetan + Atezolizumab in Advanced Solid Tumors with CDKN2A Loss
NCT06090318Phase 2Withdrawn
- Sponsor
- Rain Oncology Inc.
- Start
- May 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of milademetan in solid tumor (advanced stage), sponsored by Rain Oncology Inc.. Planned start May 2023; status: withdrawn.
02
Drugs
milademetan
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06090318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06090318.